Deutsche Bank AG Sells 71,837 Shares of INmune Bio, Inc. $INMB

Deutsche Bank AG lessened its holdings in INmune Bio, Inc. (NASDAQ:INMB) by 65.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 38,011 shares of the company’s stock after selling 71,837 shares during the quarter. Deutsche Bank AG owned approximately 0.17% of INmune Bio worth $297,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Laird Norton Wetherby Trust Company LLC raised its position in shares of INmune Bio by 3.8% in the 4th quarter. Laird Norton Wetherby Trust Company LLC now owns 34,100 shares of the company’s stock valued at $159,000 after acquiring an additional 1,250 shares during the period. Wells Fargo & Company MN raised its position in shares of INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock valued at $30,000 after acquiring an additional 2,155 shares during the period. Rhumbline Advisers raised its position in shares of INmune Bio by 14.4% in the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock valued at $150,000 after acquiring an additional 2,409 shares during the period. Barclays PLC raised its position in shares of INmune Bio by 10.2% in the 4th quarter. Barclays PLC now owns 32,019 shares of the company’s stock valued at $150,000 after acquiring an additional 2,975 shares during the period. Finally, Fermata Advisors LLC raised its position in shares of INmune Bio by 6.4% in the 1st quarter. Fermata Advisors LLC now owns 49,997 shares of the company’s stock valued at $390,000 after acquiring an additional 3,000 shares during the period. Institutional investors own 12.72% of the company’s stock.

INmune Bio Stock Down 2.9%

NASDAQ INMB opened at $2.03 on Friday. INmune Bio, Inc. has a 12-month low of $1.89 and a 12-month high of $11.64. The company has a market capitalization of $53.96 million, a PE ratio of -0.82 and a beta of 0.97. The firm’s 50 day moving average is $2.85 and its 200-day moving average is $6.07.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. As a group, sell-side analysts expect that INmune Bio, Inc. will post -2.24 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on INMB. Raymond James Financial downgraded shares of INmune Bio from a “moderate buy” rating to a “hold” rating in a research report on Monday, June 30th. BTIG Research reiterated a “neutral” rating on shares of INmune Bio in a research report on Tuesday, July 1st. Scotiabank reiterated a “sector underperform” rating on shares of INmune Bio in a research report on Tuesday, July 1st. Wall Street Zen downgraded shares of INmune Bio from a “hold” rating to a “sell” rating in a research report on Saturday, August 2nd. Finally, Maxim Group cut their price target on shares of INmune Bio from $30.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, INmune Bio presently has an average rating of “Moderate Buy” and an average target price of $18.40.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.